Ted Tarasow

HealthTell, Inc. develops healthcare diagnosing tools for individuals to monitor their health status. It offers OneTest, a new technology for the early detection and monitoring of progressive diseases and the test is simple and inexpensive, and can be performed with only a single drop of blood. The company was founded in 2010 by Stephen Albert Johnston and Neal Woodbury and is headquartered in Chandler, AZ.

Vanquish Oncology, Inc. operates as a drug development company. It focused on targeting molecular defects in specific cancer cells to create personalized oncology therapeutics for unmet and underserved cancer markets. The company was founded by Paul J. Hergenrother, Mike Handley and Ted Tarasow and is headquartered in Champaign, IL.

Transverse Medical, Inc. develops Point-Guard, a cerebral embolic protection device. The firm specializes in cerebral embolic protection, transcatheter aortic valve, surgical aortic valve and medical device development. The company was founded in 2011 and is headquartered in Golden, CO.

Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO

Lawrence Livermore National Laboratory provides nuclear testing services. The Laboratory's security needs include countering the proliferation of weapons of mass destruction and strengthening homeland security against the terrorist use of such weapons. The company was founded in 1952 and is headquartered in Livermore, CA.

NeXstar Pharmaceuticals, Inc. was a commercial biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life-threatening and other serious diseases. The firm was located in Boulder, CO.

Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients.